Washington Trust Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Washington Trust Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-209	Closed	-$3.21K	–	687
2025 Q3	$3.21K	Hold	209	–	–	﹤0.01%	643
2025 Q2	$1.96K	Hold	209	–	–	﹤0.01%	613
2025 Q1	$2.57K	Buy	209 +102	+95%	+$1.44K	﹤0.01%	600
2024 Q4	$1.42K	Hold	107	–	–	﹤0.01%	632
2024 Q3	$2.06K	Hold	107	–	–	﹤0.01%	636
2024 Q2	$2.2K	Hold	107	–	–	﹤0.01%	630
2024 Q1	$2.55K	Buy	+107	New	+$2.39K	﹤0.01%	631

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Washington Trust Advisors's SNDX Position: Q4 2025 in Review

Washington Trust Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 209 shares — an estimated $3.21K sold.

Washington Trust Advisors first reported a position in SNDX in Q1 2024 and held it in 7 quarters. The position peaked at $3.21K in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Washington Trust Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Washington Trust Advisors sold 209 Syndax Pharmaceuticals shares in Q4 2025, an estimated $3.21K.
Washington Trust Advisors first reported a position in Syndax Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Washington Trust Advisors's Syndax Pharmaceuticals position peaked at $3.21K in Q3 2025.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.